In the doxorubicin-only treatment group, genes in the prolactin signaling pathway, the allergic inflammatory airway disease pathway by IL-17F, the Wnt/Ca2+ pathway, and the osteoarthritis pathway demonstrated significant gene expression changes. This evidence concerns the gene PRL and osteoarthritis.